Treatment decisions involving Everolimus are closely tied to the disease settings recorded here: HR-positive/HER2-negative advanced breast cancer; pancreatic NET; GI/lung NET; renal cell carcinoma after VEGF-targeted therapy. Inhibits mTORC1, reducing protein synthesis, cell growth and angiogenic signaling. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. It is categorized as Targeted Therapy; mTOR Inhibitor, with Breast; Neuroendocrine Tumors; Renal Cell Carcinoma listed as the principal tumor types. The regimen field includes Everolimus + exemestane; everolimus + endocrine therapy; selected NET/RCC regimens. Those combinations are clinically meaningful because the same medicine can have a different role when paired with endocrine therapy, chemotherapy, another targeted agent, or supportive treatment. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. For clinicians reviewing the database, the drug name should therefore be interpreted together with histology, stage, prior therapy, and the relevant biomarker or eligibility requirement. Its pharmacologic class provides useful context, but does not replace disease-specific selection criteria. The wording is intended as a reference synthesis rather than a prescribing protocol and deliberately avoids individualized dose recommendations. Oncology approvals and guideline-supported uses can change over time, so contemporary labeling remains important.